Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan
Chao‐Neng Cheng, Sin‐Syue Li, Yun‐Hsuan Yeh, Ching‐Fen Shen, Jiann‐Shiuh Chen
Abstract
From January 2019 to May 2021, 11 children underwent allogeneic stem cell transplantation at our institute. Four of them received letermovir for cytomegalovirus prophylaxis. Three children, none of whom received prophylaxis, experienced cytomegalovirus reactivation. Letermovir is a promising medication for use in cytomegalovirus prophylaxis in children. Further studies are warranted.
Topics & Concepts
MedicineCytomegalovirusHematopoietic stem cell transplantationTransplantationCytomegalovirus infectionStem cellHematopoietic cellPediatricsImmunologyInternal medicineHaematopoiesisHuman immunodeficiency virus (HIV)Human cytomegalovirusHerpesviridaeViral diseaseVirusBiologyGeneticsCytomegalovirus and herpesvirus researchNeonatal Health and BiochemistryHerpesvirus Infections and Treatments